Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
Sponsor: Seoul St. Mary's Hospital
Summary
This study is a randomized, prospective, comparative study of the effectiveness of prophylactic entecavir treatment for HBV reactivation in past HBV infected patients (HBsAg-, HBcIgG+) with allogeneic hematopoietic stem cell transplantation.
Official title: A Randomized, Prospective, Comparative Study of the Effectiveness of Prophylactic Entecavir Treatment for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
19 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
226
Start Date
2021-08-21
Completion Date
2028-12-31
Last Updated
2025-07-18
Healthy Volunteers
No
Interventions
Baracle Tab.®
The intervention group take entecavir 0.5mg everyday by oral administration for 3 years after hematopoietic stem cell transplantation.
Locations (1)
Jeong Won Jang
Seoul, South Korea